PureTech Health Plc - ADR Stock News

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. Robert Ly...

PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) shares rose 4.9% to 128p on Wednesday after the company said it had completed a successful end-of-Phase 2 meeting with the US Food and Drug Administration for deupirfenidone, its lead idiopathic pulmonary fibrosis candidate. The regulator's feedback supports advancement into a pivotal Phase 3 trial and confirms the suitability of the streamline...

BOSTON--(BUSINESS WIRE)--PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis.

BOSTON--(BUSINESS WIRE)--PureTech's Founded Entity Gallop Oncology Announces Positive Initial Topline Data for LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia.

BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.

BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.

PureTech Health plc (NASDAQ:PRTC ) Q2 2025 Earnings Call August 28, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior VP of Communications & Head of Investor Relations Eric Elenko - Co-Founder & President Luba Greenwood - Corporate Participant Robert Lyne - Interim Chief Executive Officer Sven Dethlefs - Corporate Participant Conference Call Participants Heidi Danielle Jacobson ...

BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.